Apogee Therapeutics, Inc.

APGE

NASDAQ

Healthcare

Biotechnology

Waltham, MA, US196 employeesapogeetherapeutics.com

$84.23

-0.01(-0.01%)

Mkt Cap $4.7B

$28.79

$84.34

52-Week Range

At a Glance

AI-generated

8-K

Apogee Therapeutics, Inc. entered into an Underwriting Agreement on March 24, 2026, with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC as representatives of the Underwriters to issue and sell 5,000,000 shares of common stock at $70.00 per share. The Underwriters exercised in full their option for an additional 750,000 shares, with net proceeds expected to be approximately $377.4 million after discounts and expenses.

$4.7B

Market Cap

—

Revenue

-$233M

Net Income

Employees196

Fundamentals

How The Business Makes Money

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

Material Agreement

Mar 24, 2026

Entry into a Material Definitive Agreement. On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting A

Financial Results

Mar 1, 2026

of this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherw

Regulation FD

Mar 22, 2026

of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang

Regulation FD

Jan 5, 2026

of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang

Peer Companies

Company	Price	Change	Market Cap	P/E
CGONCG Oncology, Inc. Common ...	$67.48	+1.03%	$5.7B	-31.2
CELCCelcuity Inc.	$112.58	-0.31%	$5.4B	-29.4
CNTACentessa Pharmaceuticals ...	$39.72	-0.36%	$5.3B	-14.3
XENEXenon Pharmaceuticals Inc...	$56.70	+0.02%	$4.5B	-12.5
LEGNLegend Biotech Corporatio...	$19.10	+0.26%	$3.5B	-10.7
IRONDisc Medicine, Inc.	$65.22	+0.68%	$2.5B	-9.8
AAPGASCENTAGE PHARMA GROUP IN...	$26.61	+1.26%	$2.5B	-11.3
ZLABZai Lab Limited	$20.39	+0.22%	$2.3B	-11.0

Analyst View

Company Profile

CIK0001974640

ISINUS03770N1019

CUSIP432705309

Phone650-394-5230

Address221 Crescent Street, Waltham, MA, 02453, US

SEC EDGAR